跳轉至內容
Merck
全部照片(1)

重要文件

R3530

Sigma-Aldrich

Rifabutin

>98% (HPLC), powder, antibiotic

同義詞:

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C46H62N4O11
CAS號碼:
72559-06-9
分子量：:
847.00
分類程式碼代碼:
12352200
NACRES:
NA.77

產品名稱

Rifabutin, >98% (HPLC), powder

品質等級

100

化驗

>98% (HPLC)

形狀

powder

儲存條件

protect from light

溶解度

DMSO: >5 mg/mL

抗生素活性譜

neoplastics

作用方式

enzyme | inhibits

起源

Johnson & Johnson

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

[N+H]1(CCC2(NC3=C4NC(=O)\C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](\C=C\O[C@]5(Oc6c(c(c(c(c6C)[O-])C4=O)C3=N2)C5=O)C)OC)C)OC(=O)C)C)O)C)O)C)\C)CC1)CC(C)C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

InChI 密鑰

ATEBXHFBFRCZMA-VXTBVIBXSA-N

尋找類似的產品？ 前往 產品比較指南

生化／生理作用

Rifabutin is an antibiotic; antitumor.
Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.

特點和優勢

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
0000426240
0000426240
0000420621
0000420621
0000311792

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

C Y Tay et al.
Alimentary pharmacology & therapeutics, 36(11-12), 1076-1083 (2012-10-18)
Helicobacter pylori eradication rates with standard triple therapy are declining worldwide. The optimal management of H. pylori is evolving and new treatment combinations for antibiotic resistant H. pylori strains are required, especially for patients with penicillin allergy. To review the
Jakko van Ingen et al.
American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)
Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug
Matthew D Hickey et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(4), 457-461 (2013-03-26)
Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from
J P Gisbert et al.
Alimentary pharmacology & therapeutics, 35(8), 941-947 (2012-03-01)
In some cases, Helicobacter pylori infection persists even after three eradication treatments. To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. Multicentre, prospective study. In whom the following three treatments had
Kelly E Dooley et al.
Journal of acquired immune deficiency syndromes (1999), 62(1), 21-27 (2012-10-19)
Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF
查看所有相關論文

文章

用於免疫學研究的生物活性分子

提供用於免疫系統信號靶點鑑定/驗證以及抗生素、抗病毒藥物和抗真菌藥物的生物活性小分子。

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務